Logo image of SLXN

SILEXION THERAPEUTICS CORP (SLXN) Stock Fundamental Analysis

NASDAQ:SLXN - Nasdaq - KYG1281K1224 - Common Stock - Currency: USD

1  +0.02 (+1.54%)

Premarket: 0.9999 0 (-0.01%)

Fundamental Rating

2

SLXN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. SLXN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLXN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SLXN had negative earnings in the past year.
In the past year SLXN has reported a negative cash flow from operations.
SLXN Yearly Net Income VS EBIT VS OCF VS FCFSLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 500K -500K -1M

1.2 Ratios

With an excellent Return On Assets value of -8.85%, SLXN belongs to the best of the industry, outperforming 86.93% of the companies in the same industry.
SLXN has a better Return On Equity (-20.80%) than 86.40% of its industry peers.
Industry RankSector Rank
ROA -8.85%
ROE -20.8%
ROIC N/A
ROA(3y)1.45%
ROA(5y)N/A
ROE(3y)3.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLXN Yearly ROA, ROE, ROICSLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

SLXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLXN Yearly Profit, Operating, Gross MarginsSLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SLXN has been reduced compared to 1 year ago.
SLXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLXN Yearly Shares OutstandingSLXN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M
SLXN Yearly Total Debt VS Total AssetsSLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SLXN has an Altman-Z score of 0.69. This is a bad value and indicates that SLXN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.69, SLXN is in the better half of the industry, outperforming 65.90% of the companies in the same industry.
SLXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.69
ROIC/WACCN/A
WACCN/A
SLXN Yearly LT Debt VS Equity VS FCFSLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.74 indicates that SLXN should not have too much problems paying its short term obligations.
SLXN has a worse Current ratio (1.74) than 79.33% of its industry peers.
A Quick Ratio of 1.74 indicates that SLXN should not have too much problems paying its short term obligations.
SLXN has a worse Quick ratio (1.74) than 78.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.74
SLXN Yearly Current Assets VS Current LiabilitesSLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for SLXN have decreased strongly by -1360.45% in the last year.
EPS 1Y (TTM)-1360.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-957.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -59.44% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3081.05%
EPS Next 2Y-112.95%
EPS Next 3Y-76.08%
EPS Next 5Y-59.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLXN Yearly EPS VS EstimatesSLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLXN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLXN Price Earnings VS Forward Price EarningsSLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLXN Per share dataSLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as SLXN's earnings are expected to decrease with -76.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-112.95%
EPS Next 3Y-76.08%

More info and screens

0

5. Dividend

5.1 Amount

SLXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILEXION THERAPEUTICS CORP

NASDAQ:SLXN (5/1/2025, 9:31:00 PM)

Premarket: 0.9999 0 (-0.01%)

1

+0.02 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)N/A N/A
Inst Owners11.97%
Inst Owner ChangeN/A
Ins Owners2.29%
Ins Owner Change0%
Market Cap8.69M
Analysts82.86
Price Target5.1 (410%)
Short Float %3.27%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.42
P/tB 3.42
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.85%
ROE -20.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)1.45%
ROA(5y)N/A
ROE(3y)3.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.74
Altman-Z 0.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1360.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-957.33%
EPS Next Y-3081.05%
EPS Next 2Y-112.95%
EPS Next 3Y-76.08%
EPS Next 5Y-59.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.21%
OCF growth 3YN/A
OCF growth 5YN/A